Chemistry:Paliroden
Paliroden (INN; developmental code names SR-57667 and SR-57667B) is a drug which was under development for the treatment of Alzheimer's disease and Parkinson's disease but was never marketed.[1][2] It is taken orally.[1] The exact mechanism of action of the drug does not appear to have been disclosed,[1] but it has been found to stimulate neurogenesis in preclinical research.[3] It was under development by sanofi-aventis.[1] Paliroden reached phase 2 clinical trials for Alzheimer's disease and Parkinson's disease prior to the discontinuation of its development in 2007.[1][2] It is an analogue and follow-on drug of xaliproden (SR-57746; SR-57746A), which is a serotonin 5-HT1A receptor agonist and neurogenesis stimulant that reached phase 3 trials for similar indications but also did not complete development.[4]
See also
- Cyclized phenethylamine
- List of investigational Parkinson's disease drugs
- Xaliproden
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Paliroden". 2 October 2007. https://adisinsight.springer.com/drugs/800013042.
- ↑ 2.0 2.1 "Delving into the Latest Updates on Paliroden with Synapse". 4 April 2026. https://synapse.patsnap.com/drug/bf19892eabb747c990b4fbd11d17dd9c.
- ↑ "Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis". Current Alzheimer Research 3 (1): 35–36. February 2006. doi:10.2174/156720506775697070. PMID 16472201.
- ↑ "Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs". Journal of Alzheimer's Disease 34 (1): 1–114. 2013. doi:10.3233/JAD-121729. PMID 23186990. "The development of many drugs interacting with neurotrophic factors was terminated. The most advanced drug, xaliproden (SR-57746A, Xaprila; sanofi), a 5-HT1A agonist and stimulator of endogenous neurotrophin synthesis, did not meet the cognition endpoints in Phase III trials in AD patients, which applies also to paliroden (SR-57667B; with a biphenyl instead of the β-naphtyl in xaliproden; sanofi, [204]). The lessons learnt from the xaliproden clinical trials were discussed [205]. The biological characterization was reviewed [206].".
 |  |
